[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchoscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchoscopy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,85,118,147,174,208,229,259,291,313,335],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100644397","feasibility-and-preliminary-performance-of-an-ai-prototype-for-digital-rose-during-ebus-tbna-and-peripheral-tbna-a-prospective-pilot-study-ai-rose-feas-100644397",false,"NCT07662967","Feasibility and Preliminary Performance of an AI Prototype for Digital ROSE During EBUS-TBNA and Peripheral TBNA: a Prospective Pilot Study (AI-ROSE-FEAS)","Preliminary Feasibility and Diagnostic Performance of an Investigational Artificial Intelligence Prototype for Digital Rapid On-Site Evaluation (ROSE) of Cytological Slides During Diagnostic Bronchoscopy With Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) and Peripheral Transbronchial Needle Aspiration: a Prospective Monocentric Pilot Study (AI-ROSE-FEAS)","AI-ROSE-FEAS","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Clinical indication for diagnostic bronchoscopy with EBUS-TBNA for mediastinal lymphadenopathy and\u002For TBNA on peripheral lung lesions, according to ACCP\u002FERS-ESTS guidelines and the Unit's diagnostic pathways.\n* The procedure will be performed in two-person mode with IP-ROSE performed as per the center's SOP.\n* Ability to provide written informed consent.\n* Willingness to undergo the required follow-up.\n\nExclusion Criteria\n\n* Absolute contraindications to bronchoscopy.\n* Known histological diagnosis of the target lesion (except re-staging).\n* Concomitant interventional procedures that alter the standard sequence.\n* Inability to provide written informed consent.\n* Any condition that, in the investigator's judgment, compromises patient safety or the reliability of the data.","ALL","18 Years",{"count":20,"type":21},65,"ESTIMATED","6 Months","OBSERVATIONAL","Rapid On-Site Evaluation (ROSE) of cytological slides obtained during EBUS-TBNA improves diagnostic yield by providing real-time adequacy assessment and preliminary diagnostic orientation after each needle pass. In centers without a dedicated cytopathologist, ROSE is performed by a second interventional pulmonologist acting as a dedicated ROSE operator (interventional pulmonologist-performed ROSE, IP-ROSE), a model associated with good but variable diagnostic performance compared to cytopathologist-performed ROSE.\n\nThis study evaluates the feasibility and preliminary diagnostic performance of an investigational artificial intelligence prototype for digital ROSE. The prototype, developed in-house by the Principal Investigator, analyzes microscopic images of Diff-Quik stained cytological slides acquired through a dedicated digital microscope, together with basic clinical data, via API calls to a multimodal AI model. It produces two outputs: sample adequacy (appropriate\u002Fnot appropriate) and malignancy suspicion (benign\u002Fmalignant), each with a confidence score. The AI output is recorded in the study database for research purposes only and is not shown to the operator in real time; it does not influence clinical decisions during the procedure.\n\nThe study is a prospective, monocentric, observational pilot study enrolling 65 adult patients undergoing EBUS-TBNA or peripheral TBNA with IP-ROSE at a single interventional pulmonology unit. The primary statistical unit is the individual ROSE slide, with an expected 130 to 160 evaluable slides. Co-primary endpoints are: (1) technical feasibility of the AI prototype, defined as the proportion of slides with valid AI output within 90 seconds; and (2) AI accuracy for sample adequacy assessment compared to the definitive cytopathological diagnosis, with an expected 95% confidence interval precision of ±5.5%. Secondary endpoints include AI accuracy for malignancy suspicion, agreement between the AI prototype and the IP-ROSE operator, and AI output latency.\n\nThe AI prototype is not a commercially approved or CE-marked medical device. It was developed internally by the Principal Investigator for research purposes and is evaluated exclusively within this study. Data from this pilot study will inform the design of a subsequent confirmatory non-inferiority trial, which will be the subject of separate registration and ethical approval.",[26,27,28,29,30,31,32],"Lung Neoplasms","Bronchoscopy","AI (Artificial Intelligence)","Mediastinal ( Chest) Masses","Mediastinal Lymphadenopathy","EBUS Guided Transbronchial Needle Aspiration","Lung Cancer (Diagnosis)",[34,35],"bronchoscopy","artificial intelligence","NOT_YET_RECRUITING","2026-06-17",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-03",{"name":46,"class":47},"Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100640851","safety-of-bronchoscopy-in-patients-with-interstitial-lung-disease-100640851","NCT07627594","Safety of Bronchoscopy in Patients With Interstitial Lung Disease","Safety of Bronchoscopy in Patients With Interstitial Lung Disease: A Prospective, Observational, Multicentre, International Study","SaBrILD","Inclusion Criteria:\n\n* Consecutive adult (≥18 years old) patients with suspected or confirmed ILD who need to undergo bronchoscopy as part of their routine clinical practice,\n* Patients able to understand and sign an informed consent\n\nExclusion Criteria:\n\n* Patients who refused the study partecipation;\n* Patients with contraindications to bronchoscopy",{"count":57,"type":21},427,"Bronchoscopy is an essential technique, routinely used in the differential diagnosis workup of many Interstitial Lung Diseases (ILDs) and in referral centres is a common procedure. Bronchoalveolar lavage (BAL), bronchial and transbronchial biopsies with forceps and cryoprobes, and lymph node sampling with endosonography represent the most used sampling techniques in these patients. However, patients with ILDs refer to medical attention in a wide range of clinical conditions from mild functional impairment, with absent or few respiratory symptoms, to severe lung involvement with low exercise tolerance and\u002For chronic respiratory failure. In these patients, a balance between benefits and risk, i.e. to the safety and diagnostic utility of bronchoscopy should be always carefully evaluated. Moreover, there is a wide variability in adverse events entity and frequency depending by procedures performed during bronchoscopy.\n\nDespite its crucial utility, only few data are available in the literature on the safety of bronchoscopy in patients with ILDs and limited data on the utility and safety of this sampling technique are present in patients with AE-ILDs.\n\nThe primary aim of this study is to assess the overall rate of complications occurring within 24 hours after bronchoscopy. Study rate and type of complications occurring during the endoscopic procedure, within 30 days after bronchoscopy, in patients with AE-ILDs, among fibrotic Vs non-fibrotic ILD, and according to each employed sampling technique will be also recorded.",[60,27,61,62,63,64,65,66],"Interstitial Lung Disease (ILD)","Bronchoalveolar Lavage (BAL)","Acute Exacerbation","Cryobiopsy","Transbronchial Biopsy","Endosonography","Pulmonary Fibrosis",[68,69,70,71,72,73,74],"ILD","BAL","acute exacerbation","cryobiopsy","transbronchial biopsy","interstitial lung disease","pulmonary fibrosis","2026-05-29",{"date":77,"type":40},"2026-06-04",{"date":79,"type":21},"2026-06-01",{"date":81,"type":21},"2028-05-30",{"name":83,"class":47},"University of Milan",11,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":4,"leadSponsor":114,"locationsCount":117},"100093036","collection-of-lung-fluid-and-tissue-samples-for-research-100093036","NCT00471250","Collection of Lung Fluid and Tissue Samples for Research","Research Respiratory Tract Procedures","* HEALTHY VOLUNTEER INCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES:\n\n  1. 18 to 75 years of age inclusive\n  2. Enrolled without regard to gender, race, or ethnicity\n  3. NIH staff are eligible\n  4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n  5. Able and willing to complete the informed consent process\n  6. Able and willing to arrange to have another person drive them home after the procedure\n  7. Able and willing not to eat or drink anything for 6 hours prior and 2 hours after the procedure\n  8. Willing to donate blood and respiratory tract samples for storage to be used for future research\n  9. In good general health without clinically significant medical history\n  10. Physical examination without clinically significant findings\n  11. Screening laboratory tests without clinically significant abnormalities:\n* Complete blood count with differential\n* Serum chemistries including creatinine, blood urea nitrogen, glucose, liver enzymes and function tests, electrolytes\n* HIV test and hepatitis serologies (HBsAg; HCV) if status is unknown\n* Prothrombin time, partial thromboplastin time\n* Urinalysis\n* Female subjects must have negative urine pregnancy test within 1 week of participation and continue birth control practices prior to participation\n* Chest radiograph (CXR) (if the subject has not had a CXR or computerized tomography \\[CT\\] scan of the chest within the prior 7 days)\n* Pulse oximetry\n* Electrocardiogram (ECG)\n* Treadmill exercise stress test (as indicated for history of angina or abnormalities on ECG)\n\nHEALTHY VOLUNTEER EXCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES:\n\n1. \\\u003C18 or \\>75 years old\n2. A smoking history of 10 pack-years or more, a current smoker, or tobacco free for less than a year.\n3. Positive HIV status. Subjects must have a negative FDA-approved HIV blood test. \\[Note: Results of HIV enzyme-linked immunosorbent assay (ELISA) will be documented, but a negative HIV polymerase chain reaction (PCR) test result will be sufficient for eligibility screening of subjects with positive HIV ELISA that is due to prior participation in an HIV vaccine study\\]\n4. Acute or chronic hepatitis based on viral hepatitis serologies\n5. Pregnancy or breastfeeding\n6. Any active medical problems especially bleeding disorders, significant bruising or bleeding difficulties with intramuscular (IM) injections or blood draws, use of anticoagulants, or pulmonary disorders including asthma\n7. History of allergic reaction to lidocaine, sedative medications like Valium Trademark or Versed Trademark, or narcotic medications like morphine or fentanyl\n8. Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past three months. (Note that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics is not excluded).\n9. Use of platelet inhibitors including aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) within 7 days of procedure\n10. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent\n\nPATIENT INCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES\n\n1. 18 to 75 years of age inclusive\n2. Known or suspected respiratory infections or infection susceptibility\n3. Enrolled without regard to gender, race, or ethnicity\n4. Must be enrolled in a concurrent NIH protocol and under the care of a primary physician outside of the NIH\n5. Able and willing to complete informed consent process\n6. Able and willing to arrange to have another person drive them home after the procedure\n7. Able and willing not to eat or drink anything for 6 hours prior and 2 hours after the procedure\n8. Willing to donate blood and respiratory tract samples for storage to be used for future research\n\nPATIENT EXCLUSION CRITERIA FOR BRONCHOSCOPY AND BRONCHOSCOPIC PROCEDURES\n\n1. \\\u003C18 or \\>75 years old\n2. History of recent\u002Facute clinically significant pulmonary compromise. This will be defined by the following criteria:\n\n   * New lung infection or change in status of chronic lung infection or significant new findings on chest x-ray or CT scan\n   * Asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past two years, or that required the use of oral or parenteral corticosteroids during the past two years\n   * Clinically significant reactive airway disease that does not respond to bronchodilators\n   * Unstable chronic lung disease such as Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis\n   * History of pulmonary hypertension\n   * Requirement of supplemental oxygen at rest\n3. Unstable angina or uncontrolled heart failure or rhythm disturbance\n4. Significant kidney or liver disease\n5. Significant anemia with a hemoglobin of less than 7.5 grams\u002Fdl.\n6. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with IM injections or blood draws, or use of anticoagulant medications\n7. Use of platelet inhibitors including aspirin and NSAIDs within 7 days of procedure or clopidogrel (Plavix Trademark) within 14 days of procedure or the inability to safely stop platelet inhibitors for 7-14 days prior to procedures\n8. History of allergic reaction to lidocaine, sedative medications like Valium Trademark or Versed Trademark, or narcotic medications like morphine or fentanyl\n9. Pregnancy or breastfeeding\n10. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent\n\nHEALTHY VOLUNTEER INCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, AND NASAL POTENTIAL DIFFERENCE MEASUREMENT:\n\n1. \\>= 5 years old\n2. Enrolled without regard to gender, race, or ethnicity\n3. NIH staff are eligible\n4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n5. Able and willing to complete the informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n7. Stable vital signs\n\nHEALTHY VOLUNTEER EXCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, AND NASAL POTENTIAL DIFFERENCE MEASUREMENT:\n\n1. \\\u003C5 years old\n2. History of frequent colds or significant uncontrolled hay fever symptoms, recent or active upper respiratory tract infection, such as a cold or sinusitis, or chronic sinus infection or congestion\n3. History of turbinectomy or significant nasal pathology that would preclude obtaining mucosal scrape biopsies or other measures\n4. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with IM injections or blood draws, or use of anticoagulant medications\n5. The use of nasal steroids in the past 6 weeks\n6. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent\n\nPATIENT INCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, NASAL POTENTIAL DIFFERENCE MEASUREMENT, SPUTUM INDUCTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\>= 5 years old\n2. Known or suspected infections or infection susceptibility\n3. Enrolled without regard to gender, race, or ethnicity\n4. Must be enrolled in a concurrent NIH protocol and under the care of a primary physician outside of the NIH\n5. Able and willing to complete informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n\nPATIENT EXCLUSION CRITERIA FOR NASAL MUCOSAL BIOPSY, NASAL NITRIC OXIDE MEASUREMENT, NASAL POTENTIAL DIFFERENCE MEASUREMENT, SPUTUM INDUCTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\\u003C5 years old\n2. Significant uncontrolled hay fever symptoms or recent or active upper respiratory tract infection, such as a cold or sinusitis\n3. History of turbinectomy or significant nasal pathology that would preclude obtaining mucosal scrape biopsies or other measures\n4. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), significant bruising or bleeding difficulties with IM injections or blood draws, or use of anticoagulant medications\n5. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.\n\nHEALTHY VOLUNTEER INCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE COLLECTION COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\>= 5 years old\n2. Enrolled without regard to gender, race, or ethnicity\n3. NIH employees or non-employees eligible\n4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n5. Able and willing to complete the informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n7. Stable vital signs\n\nHEALTHY VOLUNTEER EXCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE COLLECTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\\u003C 5 years old\n2. History of asthma or reactive airways disease\n3. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent\n\nPATIENT INCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE COLLECTION, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\>= 5 years old\n2. Known or suspected infections or infection susceptibility\n3. Enrolled without regard to gender, race, or ethnicity\n4. Must be enrolled in a concurrent NIH protocol and under the care of a primary physician outside of the NIH\n5. Able and willing to complete informed consent process\n6. Willing to donate blood and respiratory tract samples for storage to be used for future research\n\nPATIENT EXCLUSION CRITERIA FOR SPUTUM INDUCTION, EXHALED BREATH CONDENSATE, COUGH AEROSOL SAMPLING, EXHALED AEROSOL MASK SAMPLE COLLECTION, COLLECTION OF EXHALED PARTICLES, AND LCI:\n\n1. \\\u003C 5 years old\n2. Significant uncontrolled asthma or reactive airways disease\n3. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent.",true,"5 Years","100 Years",{"count":96,"type":21},550,"This study will collect fluid and tissue specimens from the lungs and nose of healthy people and people with a history of lung infections. The specimens will be examined for differences between the two groups that may be associated with susceptibility to certain infections.\n\nHealthy normal volunteers and people with a history of lung infections between 18 and 75 years of age who are followed at NIH may be eligible for this study.\n\nParticipants undergo the following procedures:\n\nMedical history and physical examination.\n\nBlood and urine tests.\n\nElectrocardiogram (ECG) and chest x-ray.\n\nTreadmill exercise stress test (for people over 45 years old with a history of chest pain or ECG abnormalities).\n\nBronchoscopy: The subject s nose and throat are numbed with lidocaine and a sedative is given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully.\n\nFluid collection during the bronchoscopy using one of the following methods:\n\n* Bronchoalveolar lavage: Salt water is injected through the bronchoscope into the lung and immediately suctioned out, washing off cells lining the airways.\n* Bronchial brushings: A brush-tipped wire enclosed in a sheath is passed through the bronchoscope and a small area of the airway tissue is gently brushed. The brush is withdrawn with some tissue adhering to it.\n* Endobronchial biopsies: Small pinchers on a wire are passed through the bronchoscope and about 1 to 2 millimeters of tissue is removed.\n* Nasal scrape: A small device is used to scrape along the inside of the nose to collect some cells.\n* Sputum induction\n* Exhaled breath condensate to obtain specimens for in vitro investigations and comparisons of both the cellular and acellular components.\n* Nasal nitric oxide production\n* Nasal potential difference\n* Exhaled aerosol mask sample collection\n* Cough aerosol collection\n* Exhaled particle collection\n* Lung Clearance Index (LCI)",[99,100,27],"Leukocyte Disorders","Respiratory Tract Diseases",[102,103,104,105,106,107,108,109],"Lung Infection Susceptibility","Bronchoalvealar lavage","Nasal Biopsy","Sputum Sample","Infection Susceptibility","Natural History","Healthy Volunteer","HV","RECRUITING",{"date":79,"type":40},{"date":113,"type":40},"2007-08-17",{"name":115,"class":116},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":117},"100621300","ai-driven-autonomous-registration-in-robotic-bronchoscopy-100621300","NCT07368829","AI-Driven Autonomous Registration in Robotic Bronchoscopy","Feasibility and Safety of Artificial Intelligence-Driven Autonomous Registration in Robotic Navigational Bronchoscopy","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Radiologically confirmed pulmonary nodules requiring preoperative localization.\n* Scheduled for robotic navigational bronchoscopy using the Bronchoscopy Robot System.\n* Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Severe cardiopulmonary dysfunction (e.g., FEV1 \\\u003C 30% predicted).\n* Coagulopathy or anticoagulation therapy that cannot be safely interrupted.\n* Pregnancy or lactation.\n* Inability to tolerate bronchoscopy under general anesthesia.",{"count":126,"type":21},20,"INTERVENTIONAL",[129],"NA","This study aims to evaluate the feasibility and safety of an artificial intelligence (AI)-driven autonomous registration technology in robotic navigational bronchoscopy. A total of 20 patients with pulmonary nodules requiring localization will be enrolled. The Langhe Bronchoscopy Robot System equipped with AI-based autonomous registration software will be used. Primary outcomes include the success rate of autonomous registration and the rate of manual intervention during the process. Secondary outcomes encompass registration time, complication rates, and nodule localization success.",[132,27,133],"Lung Nodules","Localization Efficiency",[135,136,137],"Artificial Intelligence","Robotic Bronchoscopy","Pulmonary Nodule","2026-04-09",{"date":140,"type":40},"2026-04-13",{"date":142,"type":40},"2026-03-01",{"date":144,"type":21},"2026-06-30",{"name":146,"class":47},"Ruijin Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":127,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":117},"100632764","chewing-gum-and-cold-gargle-on-post-bronchoscopy-symptoms-100632764","NCT07517926","Chewing Gum and Cold Gargle on Post-Bronchoscopy Symptoms","The Effect of Chewing Gum and Gargling With Cold Water on Post-Bronchoscopy Sore Throat, Dysphagia, and Patient Satisfaction: A Randomized Controlled Study","Inclusion Criteria:\n\n* • Being 18 years of age or older\n\n  * Having a scheduled diagnostic bronchoscopy\n  * Having normal speech and swallowing functions\n  * Being conscious and able to communicate\n  * Volunteering to participate in the study\n\nExclusion Criteria:\n\n* • Complications during bronchoscopy\n\n  * Gastroesophageal reflux\n  * Use of non-steroidal anti-inflammatory drugs\n  * Receiving steroid treatment within 1 week prior to the procedure\n  * Active infection or disease in the mouth or throat area\n  * History of allergy or intolerance to the procedure\n  * Previous anatomical or functional impediment to chewing gum or gargling",{"count":155,"type":21},100,[129],"This study aims to evaluate the effects of chewing gum and gargling with cold water on common post-bronchoscopy symptoms, such as sore throat and difficulty swallowing (dysphagia). Bronchoscopy is a procedure that can cause temporary throat discomfort. In this randomized controlled trial, patients will be divided into groups to receive either chewing gum, cold water gargle, or standard care. The researchers will then measure and compare patient satisfaction levels and the severity of throat symptoms to determine if these simple interventions can improve patient comfort after the procedure.",[159,160,161,27],"Sore Throat","Dysphagia","Patient Satisfaction",[27,159,160,163,164,165],"Chewing Gum","Cold Water Gargle","Nursing Care","2026-04-07",{"date":140,"type":40},{"date":169,"type":40},"2025-11-10",{"date":171,"type":21},"2026-05-11",{"name":173,"class":47},"Ankara University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":117},"100597373","shape-sensing-robotic-assisted-bronchoscopy-for-diagnosis-of-peripheral-pulmonary-nodules-in-korea-100597373","NCT07057648","Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea","Shape-sensing Robotic-assisted Bronchoscopy (ssRAB) for Diagnosis of Peripheral Pulmonary Nodules: A Prospective Cohort Study in Korea (the ULSAN-ION Study)","ULSAN-ION","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Solid or part-solid peripheral pulmonary nodules confirmed on chest computed tomography (CT)\n* Patients requiring histological diagnosis as determined by the treating physician\n* Patients eligible for bronchoscopy procedure\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or equivalent functional status allowing procedure under sedation or general anesthesia\n\nExclusion Criteria:\n\n* Pure ground glass opacity nodules\n* Bleeding tendency defined as platelet count less than 50,000\u002FμL or International Normalized Ratio (INR) greater than 1.5\n* Severe cardiopulmonary dysfunction precluding deep sedation or general anesthesia\n* Pregnant or breastfeeding women\n* Life expectancy less than 6 months as assessed by the treating physician\n* Inability or unwillingness to provide informed consent\n* Absolute contraindication to bronchoscopy including:\n\n  * Severe hypoxemia (oxygen saturation \\\u003C90% on room air)\n  * Severe pulmonary hypertension\n  * Recent myocardial infarction (within 6 weeks)\n  * Unstable angina\n  * Malignant arrhythmias\n* Participation in another interventional clinical trial that may interfere with study procedures or outcomes","19 Years",{"count":155,"type":21},"What is this study about? This study tests a new robotic technology to take tissue samples from lung nodules (small spots in the lungs). Some lung nodules are cancer, but doctors need a tissue sample to know for sure.\n\nWhat is the problem? Current methods to get tissue from lung nodules only work about 7 out of 10 times. When they don't work, doctors may need riskier procedures.\n\nWhat is the new technology? The new technology is called robotic bronchoscopy (ssRAB). It uses a robot with special sensors to guide a thin tube more accurately to lung nodules than current methods.\n\nWho can join? Adults aged 19 or older who have lung nodules that need tissue sampling and are healthy enough for the procedure.\n\nWhat happens? Participants will have the robotic procedure while asleep under anesthesia. The robot guides a thin tube to the lung nodule to take a small tissue sample. Participants are watched for problems and followed for 6 months.\n\nWhat are the risks and benefits? The new technology may be more accurate and safer than current methods. The main risks are small chance of lung collapse or bleeding, similar to regular procedures.\n\nWhy is this important? This study will show if the new robotic technology works well and is safe in Korea. If successful, it could help diagnose lung cancer earlier and more accurately.\n\nThis study will include 100 people at Ulsan University Hospital in Korea.",[132,186,187,188,27],"Peripheral Lung Lesions","Pulmonary Nodules","Lung Cancers",[190,191,192,193,194,132,195,196,197,198],"Shape-sensing robotic-assisted bronchoscopy","ssRAB","Robotic bronchoscopy","Peripheral lung nodules","Diagnostic yield","Navigation bronchoscopy","Lung biopsy","Korea","Prospective cohort","2026-02-10",{"date":201,"type":40},"2026-02-13",{"date":203,"type":40},"2025-07-09",{"date":205,"type":21},"2027-05-31",{"name":207,"class":47},"Ulsan University Hospital",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100612449","the-lucent-study---lung-lesion-assessment-via-bf-ucp190f-for-central-and-extended-nodal-targeting-100612449","NCT07253727","The LUCENT Study - LUng Lesion Assessment Via BF-UCP190F for Central and Extended Nodal Targeting","LUCENT","Inclusion Criteria:\n\n1. Willing and able to provide informed consent.\n2. ≥18 years of age.\n3. The target lesion(s) must be located within the inner and middle two-thirds of the lung, as determined prospectively using the Software-Assisted Method (SAM). To ensure accurate localization, SAM applies anatomical measurements to classify lesions as inner, middle, or outer third of the lung. The lesion must contact the border of the inner two-thirds region; lesions fully outside this region will be excluded from the study cohort. In addition, the lesion must be located at least two airway generations distal to the main carina, as confirmed radiographically by the bronchoscopist\n4. Target lesion: nodule ≥ 10mm or lymph node ≥ 5mm.\n5. Target lesion location documented on CT or PET report.\n6. Indicated for bronchoscopy.\n7. Bronchoscopic procedure scheduled within 30 days of the CT or PET report.\n8. Patient qualifies for a procedure using the BF-UCP190F bronchoscope and the ViziShot 2 25 needle based upon the approved indications for use for those devices.\n\nExclusion Criteria:\n\n1. Concurrently participating in another competing clinical study.\n2. Unwilling or unable to return for follow-up, e.g., plans for relocation, unsuitable transportation.\n3. Patient not suitable for flexible bronchoscopy as determined by the treating physician prior to the procedure.\n4. Currently on anticoagulation that cannot be paused, or a coagulation disorder that, in the opinion of the investigator, would pose an increased risk of bleeding.\n5. Intraprocedural identification of intrinsic and endoscopically visualized endobronchial lesion for which adequate biopsy can be obtained via endobronchial biopsy.",{"count":216,"type":21},200,"The Olympus BF-UCP190F bronchoscope combines the reach of a thinner bronchoscope with the benefit of real-time ultrasound, enabling direct lesion visualization and sampling deeper into the lung. Following promising first-in-human data, the LUCENT study aims to evaluate the utility feasibility, effectiveness and safety of this device in a multicenter setting, generating real-world evidence to inform broader adoption in global markets.",[27],"2025-11-19",{"date":221,"type":40},"2025-11-28",{"date":223,"type":21},"2025-12-01",{"date":225,"type":21},"2028-08-31",{"name":227,"class":228},"Olympus Europe SE & Co. KG","INDUSTRY",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":127,"phases":239,"briefSummary":240,"conditions":241,"keywords":246,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":117},"100593428","robotic-assisted-bronchoscopy-under-moderate-sedation-with-propofol-100593428","NCT07006311","Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol","Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol: A Single-center Pilot Study.","Robofol","Inclusion Criteria:\n\n* informed consent signed by the subject\n* aged at least 18 years\n* scheduled for bronchoscopy with moderate sedation and tracheal intubation in order to obtain at least 1 specimens of the lung via transbronchial biopsy\n* necessary periinterventional laboratory examinations needed for the bronchoscopy\n* judgement of the subject\n\nExclusion Criteria:\n\n* endobronchial lesion causing lobar atelectasis\n* inability or contraindications to undergo bronchoscopy (e.g. severe cardiopulmonary diseases, coagulation disorders, intolerance to anesthesia or endoscopic operation, psychiatric disorders or severe neurosis)\n* pregnant or lactating women",{"count":238,"type":21},30,[129],"In this study, the investigators want to find out whether robot-assisted bronchoscopy also works with moderate sedation (Propofol), as is already used in standard bronchoscopies. The study is being conducted as a pilot study. This means that it is an initial test run for a scientific investigation. The investigators are testing on a small scale whether the intervention works as predicted before a larger study is conducted.",[242,243,244,27,245],"Lung Lesions","Robotic Assisted Bronchoscopy","Propofol","Bronchoscopy Biopsy",[247,248,249,250],"Robotic-assisted bronchoscopy","robotic assisted bronchoscopy","diagnosis of lung lesions","moderate sedation","2025-09-16",{"date":253,"type":40},"2025-09-22",{"date":255,"type":40},"2025-08-14",{"date":79,"type":21},{"name":258,"class":47},"University of Zurich",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":268,"conditions":269,"keywords":274,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":117},"100589361","classification-and-prediction-of-difficult-awake-tracheal-intubation-with-flexible-bronchoscopes-100589361","NCT06953414","Classification and Prediction of Difficult Awake Tracheal Intubation With Flexible Bronchoscopes","AirWake","Inclusion Criteria:\n\n* Patients with an anticipated difficult airways scheduled for ATI:FB\n* Consent by the patient\n* Minimum 18 years of age\n\nExclusion Criteria:\n\n* Patients not scheduled for ATI:FB\n* Pregnant or breastfeeding patients\n* Consent not given by the patient",{"count":267,"type":21},313,"Airway management problems are key drivers for anesthesia-related adverse events. Awake tracheal intubation using flexible bronchoscopes with preserved spontaneous breathing (ATI:FB) is a recommended technique to manage difficult tracheal intubation in anesthesia, intensive care and emergency medicine. However, a prospective developed classification for this type of airway management is lacking. Due to the absence of a specifically tailored, validated classification for awake intubation with flexible bronchoscopes, many airway operators and institutions use classification tools that were originally developed for direct laryngoscopy, such as the percentage of glottic opening (POGO) score or Cormack-Lehane classification, although their diagnostic performance for the classification of ATI:FB is unknown. This prospective model development and validation study aims to develop two multivariable prediction models: a diagnostic prediction model to classify difficult ATI:FB after ATI:FB has been performed and a second prognostic prediction model to predict the risk for difficult ATI:FB before ATI:FB is performed. An additional aim is to develop a machine learning algorithm to evaluate ATI:FB.",[270,271,272,27,273],"Anesthesia","Airway Management","Intubation, Intratracheal","Endoscopes",[275,276,277,278,279,280,281],"Airway management","Classification","Flexible endoscopy guided intubation","Fibroptic guided intubation","Respiratory system","Laryngeal diseases","Health records","2025-05-01",{"date":284,"type":40},"2025-05-06",{"date":286,"type":40},"2025-04-30",{"date":288,"type":21},"2026-01-31",{"name":290,"class":47},"Universitätsklinikum Hamburg-Eppendorf",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":127,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100575961","fasting-durations-before-bronchoscopy-and-the-discomfort-levels-of-patients-100575961","NCT06779084","Fasting Durations Before Bronchoscopy And The Discomfort Levels Of Patients","Association Between Different Fasting Durations Before Bronchoscopy And The Discomfort Levels Of Patients Around The Procedure","Inclusion Criteria:\n\n* planned flexible bronchoscopy\n\nExclusion Criteria:\n\n* tracheostomy or intubated\n* known to be pregnant\n* significant functional or structural abnormalities of the gastrointestinal tract\n* oral intake prohibited and infeasible",{"count":299,"type":21},84,[129],"The goal of this clinical trial is to learn if patients feel more comfortable while being placed on contemporary fasting principle than on conventional fasting time during flexible bronchoscopy. The main questions it aims to answer are:\n\nTo compare the thirty levels between patients with conventional fasting time (≥ 8 hours) and those with contemporary fasting principle (clear fluids for up to 2 hours before anesthesia) during flexible bronchoscopy To compare the levels of mucosal dryness between two groups of patients during flexible bronchoscopy To compare the levels of hunger between two groups of patients during flexible bronchoscopy To compare the levels of tiredness between two groups of patients during flexible bronchoscopy To compare the levels of fatigue between two groups of patients during flexible bronchoscopy To compare the levels of nausea\u002Fvomiting between two groups of patients during flexible bronchoscopy\n\nParticipants will:\n\nBeing placed on fasting either using conventional fasting time (≥ 8 hours) or with contemporary fasting principle (clear fluids for up to 2 hours before anesthesia) Being asked to respond to questions regarding thirsty, mucosal dryness, hunger, tiredness, fatigue, and nausea\u002Fvomiting in a visual analogue scale of 0 to 10",[27,303],"Fasting ( 6H for Solid ; 2H for Clear Fluid )","2025-01-12",{"date":306,"type":40},"2025-01-16",{"date":308,"type":21},"2025-01",{"date":310,"type":21},"2026-12",{"name":312,"class":47},"National Taiwan University Hospital",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":127,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100570578","muscle-relaxant-effect-and-safety-of-mivacurium-chloride-and-succinylcholine-for-bronchoscopy-100570578","NCT06709066","Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy","Inclusion Criteria:\n\n1. Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.\n2. Aged between 18 and 60 years.\n3. Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.\n4. Patients voluntarily participate and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with known allergies to any of the drugs involved in the study.\n2. Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.\n3. Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.\n4. Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.\n5. Patients who have used medications affecting neuromuscular transmission function before the procedure.\n6. Pregnant or breastfeeding patients.\n7. Patients who have experienced extensive burns, acid-base imbalance, or electrolyte disturbances within the past six months.\n8. Patients known or suspected to be homozygous for the atypical gene for plasma cholinesterase.","60 Years",{"count":321,"type":21},240,[129],"The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are:\n\n* Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine?\n* How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine.\n\nParticipants will:\n\n* Receive either mivacurium chloride (0.14 mg\u002Fkg induction bolus + 0.5 mg\u002Fkg\u002Fh maintenance infusion) or succinylcholine (1 mg\u002Fkg induction bolus + 5 mg\u002Fkg\u002Fh maintenance infusion) as a muscle relaxant during bronchoscopy.\n* Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure.\n* Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.",[270,27,325],"Muscle Relaxants","2024-11-26",{"date":328,"type":40},"2024-11-29",{"date":330,"type":21},"2024-11-20",{"date":332,"type":21},"2025-12-31",{"name":334,"class":47},"Peng Liang",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":343,"studyType":23,"phases":4,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":117},"100555399","fbs-asap-fibrobronchoscopy-in-aspiration-pneumonia-in-the-emergency-department-100555399","NCT06511583","FBS-ASaP: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department","FBS-ASaP","Inclusion Criteria:\n\nAll adult patients who access the Emergency Department with a diagnosis of aspiration pneumonia and for whom the referring physician determines the need for aspiration of secretions or ingesta. Patients must have at least one of the following criteria\n\n* Radiological evidence of pneumonia (Chest X-ray\u002FCT scan\u002FChest ultrasound)\n* Clinical diagnosis of aspiration pneumonia\n* Presence of secretions in the upper airways\n* Respiratory distress in a dysphagic patient\n* Need for oxygen therapy or need to increase FiO2 in patients already on home oxygen therapy\n\nExclusion Criteria:\n\n* Lack of consent\n* Age \\< 18 years\n* Pregnancy\n* Hemorrhagic diathesis\n* Malignant cardiac arrhythmias (VT, AV block excluding first-degree AV block)\n* Severe airway obstruction",{"count":155,"type":21},"30 Days","Non-Profit Prospective Observational Pilot Study\n\nThe study will have an overall duration of 3 years, with patient enrollment starting after ethical committee approval.\n\nIn this study, all patients with a diagnosis of aspiration pneumonia who require aspiration of secretions or ingesta in the Emergency Department will be considered. A registry will be created with the patients\\' data, noting the type of procedure performed: laryngotracheal aspiration with a probe or with fibrobronchoscopy.\n\nThis observational registry pilot study aims to evaluate the utility and adverse events related to the use of aspiration via videobronchoscopy performed in the Emergency Department and to compare the clinical outcomes of patients undergoing bronchoscopy with those treated only with blind laryngotracheal aspiration using a probe.",[346,27],"Aspiration Pneumonia",[348,27,349,350,351,352,353],"Aspiration pneumonia","toilette","interventional pulmunology","respiratory failure","pneumonia","bacterial pneumonia","2024-07-15",{"date":356,"type":40},"2024-07-22",{"date":358,"type":40},"2024-02-05",{"date":360,"type":21},"2027-03-05",{"name":362,"class":47},"Azienda Ospedaliero-Universitaria Careggi"]